Nirsevimab for preventing respiratory syncytial virus infection in preterm infants: a descriptive analysis of 111 cases
10.3760/cma.j.cn113903-20250825-00453
- VernacularTitle:尼塞韦单抗预防早产儿呼吸道合胞病毒感染的描述性研究：111例分析
- Author:
Wanxian ZHANG
1
;
Xiuying TIAN
1
Author Information
1. 天津市中心妇产科医院新生儿科，天津 300100
- Publication Type:Journal Article
- Keywords:
Nirsevimab;
Respiratory syncytial virus;
Prevention;
Preterm infant
- From:
Chinese Journal of Perinatal Medicine
2025;28(12):1052-1056
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the real-world safety and preliminary clinical outcomes of Nirsevimab in preterm infants.Methods:This descriptive study retrospectively enrolled 111 preterm infants who voluntarily received respiratory syncytial virus (RSV) monoclonal antibody at Tianjin Central Hospital of Gynecology Obstetrics between October 1, 2024, and June 30, 2025. Data collection included baseline characteristics, comorbidities, Nirsevimab administration details, and telephone follow-up for RSV-related infections, hospitalizations, and serious adverse events. Descriptive statistics were applied.Results:(1) The cohort had a mean gestational age of (30.9±2.8) weeks (range 24 +3-36 +6 weeks) and birth weight (1 479±475) g (range 680-2 720 g). (2) Comorbidities included retinopathy of prematurity (29.7%, 33/111), bronchopulmonary dysplasia (22.5%, 25/111), congenital heart disease (3.6%, 4/111), and necrotizing enterocolitis (0.9%, 1/111). (3) Median age at Nirsevimab administration was 46 d (range 3-121 d), with median corrected gestational age of 37 +5 weeks (range 33 +5-49 +6 weeks) and median weight 2 300 (range 1 680-4 870) g. (4) No adverse reactions occurred within one week post-injection. Twenty-six infants (23.4%) received Nirsevimab on the same day as other vaccines. Among the 50 cases with complete blood count and C-reactive protein testing within one week before and after Nirsevimab injection, only one (2.0%) showed elevated C-reactive protein levels post-injection; increased eosinophil percentages were observed in 24 cases (48.0%), while the remaining 26 cases (52.0%) showed decreased percentages. Administration of Nirsevimab occurred during the RSV epidemic season in 79 infants (71.2%), with the remaining 32 cases (28.8%) vaccinated outside the epidemic season. (5) During follow-up to median age 171 d (range 84-380 d), no mortality, RSV-related lower respiratory infections, hospitalizations, or intensive care unit admissions occurred. Nineteen cases (17.1%) required outpatient/emergency visits for acute respiratory infections without wheezing, including nine pneumonia (8.1%) and two otitis media (1.8%) cases. Fifteen (13.5%) were hospitalized, one (0.9%) required intensive care unit care, and none needed mechanical ventilation. Conclusion:Nirsevimab demonstrated favorable safety profiles for preventing RSV in preterm infants with no confirmed RSV cases during follow-up.
